{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=64",
    "query": {
      "condition": "Melanoma Neoplasms",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 2209,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T00:44:14.765Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03126461",
      "title": "SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "SAbR",
          "type": "RADIATION"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-03-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126461"
    },
    {
      "nct_id": "NCT05470283",
      "title": "Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor",
        "Metastatic Melanoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "OBX-115",
          "type": "DRUG"
        },
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Furosemide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-09-07",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470283"
    },
    {
      "nct_id": "NCT04139902",
      "title": "Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "Dostarlimab (TSR-042) (singly)",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab (TSR-042) and TSR-022 (combination)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diwakar Davar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2020-06-12",
      "completion_date": "2029-12-15",
      "has_results": true,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Washington",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04139902"
    },
    {
      "nct_id": "NCT01068470",
      "title": "Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Kidney Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-29",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Beaumont, California",
      "locations": [
        {
          "city": "Beaumont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068470"
    },
    {
      "nct_id": "NCT00004141",
      "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte-macrophage colony-stimulating factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 46,
      "start_date": "1998-08",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004141"
    },
    {
      "nct_id": "NCT01738139",
      "title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "C-KIT Tyrosine Kinase Protein Overexpression",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Gastrointestinal Stromal Tumor",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Unresectable Melanoma",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2013-02-19",
      "completion_date": "2023-12-13",
      "has_results": false,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01738139"
    },
    {
      "nct_id": "NCT03804255",
      "title": "Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Colorectal Carcinoma",
        "Community Practice",
        "Lung Carcinoma",
        "Melanoma",
        "Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2019-01-08",
      "completion_date": "2020-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03804255"
    },
    {
      "nct_id": "NCT02752074",
      "title": "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "pembrolizumab + epacadostat",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab + placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 706,
      "start_date": "2016-06-21",
      "completion_date": "2019-08-16",
      "has_results": true,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02752074"
    },
    {
      "nct_id": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Autologous Dendritic Cells (DC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Autologous Lymphocyte Infusion (ALI)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2006-02",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-02-21",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313508"
    },
    {
      "nct_id": "NCT04368247",
      "title": "Skin Fluorescent Imaging (SFI) System in Patients With Nevi",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nevus",
        "Dysplasia; Epithelial"
      ],
      "interventions": [
        {
          "name": "Skin Fluorescent Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Orlucent, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-08-10",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-29T00:44:14.765Z",
      "location_count": 4,
      "location_summary": "Fremont, California • Northridge, California • Vallejo, California + 1 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368247"
    }
  ]
}